Protective Effects of beta 1/2 Adrenergic Receptor Deletion in a Model of Oxygen-Induced Retinopathy

作者:Dal Monte Massimo; Cammalleri Maurizio; Mattei Elisabetta; Filippi Luca; Bagnoli Paola*
来源:Investigative Ophthalmology & Visual Science, 2015, 56(1): 59-73.
DOI:10.1167/iovs.14-15263

摘要

PURPOSE. beta-adrenergic receptors (beta-ARs) regulate angiogenesis in proliferative retinopathies. We studied the effects of beta 1/2-AR deletion in a model of oxygen-induced retinopathy (OIR) to confirm the role of beta 1- and/or beta 2-ARs in regulating angiogenesis and to get insights into the role of beta 3-ARs. METHODS. Mice with beta 1/2-AR deletion (KO) were used. Levels of norepinephrine (NE), beta 3-ARs, transcription, and proangiogenic factors were evaluated. Retinas were analyzed for avascular area and neovascular tufts in the superficial plexus. Deep plexus and blood-retinal barrier (BRB) were also analyzed. Neovascularization, proangiogenic factors, protein kinase A (PKA) activity, and nitrite production were assessed after BRL 37344, a beta 3-AR agonist. RESULTS. Oxygen-induced retinopathy was characterized by NE upregulation with higher levels in wild type (WT) than in KO. Wild type and KO displayed comparable levels of beta 3-ARs, transcription, and proangiogenic factors, but differed in VEGF receptor (VEGFR) expression with VEGFR-1 in WT lower than in KO and VEGFR-2 in WT higher than in KO. Blood-retinal barrier dysfunction did not differ between WT and KO. Vascular abnormalities in the superficial plexus were abolished by beta 1/2-AR deletion, which also helped the development of the deep plexus. In both WT and KO, beta 3-AR agonism, acting through the nitric oxide pathway, caused enhanced neovascular responses with increased levels of VEGF. CONCLUSIONS. We confirm that beta 1- and beta 2-ARs play a pivotal role in retinal angiogenesis. In their presence, beta 3-ARs potentiate angiogenic responses, whereas, in their absence, beta 3-ARs sustain the angiogenic drive. These results suggest beta-ARs as promising targets for therapies aimed to counteract proliferative retinopathies.

  • 出版日期2015-1